ArticleFrontiers in immunology2026
Smilax glabra flavonoids ameliorate non-alcoholic steatohepatitis by regulating PKM2-dependent glycolysis and suppressing AIM2 inflammasome activation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nonalcoholic steatohepatitis (NASH) is a prevalent chronic liver disease characterized by hepatic steatosis, persistent inflammation and progressive liver damage. Methods: This study aimed to investigate the protective effects of SGF against high-fat diet (HFD)-induced NASH in mice, with emphasis on PKM2-mediated glycolysis and AIM2 inflammasome activation. C57BL/6J mice were fed an HFD for 20 weeks to establish a NASH model and concurrently treated with SGF (30 or 90 mg/kg/day) or empagliflozin (EMPA). Comprehensive assessments, including biochemical detection, histological staining and molecular biological verification, were performed. Results: SGF markedly attenuated HFD-induced obesity, dyslipidemia, hepatic steatosis, fibrosis and hepatocellular damage, mitigated hepatic oxidative stress and restored mitochondrial structure integrity. Mechanistically, SGF restrained glycolytic metabolism by downregulating the expression of HK2, p-PKM2, and LDHA and by reducing pyruvate and lactate production. Besides, SGF mitigated AIM2 inflammasome activation and decreased the levels of AIM2, ASC, caspase-1, and IL-1β. Mechanistic validation confirmed that PKM2 was abundantly expressed in macrophages, and PKM2 overexpression partially abrogated the inhibitory effects of SGF on glycolysis and AIM2 inflammasome signaling. Co-culture assays further demonstrated that PKM2 overexpression in RAW264.7 macrophages exacerbated lipid deposition, oxidative stress, glycolysis, and AIM2 inflammasome activation in AML-12 hepatocytes, thereby counteracting the hepatoprotective effects of SGF. Conclusion: SGF effectively ameliorates HFD-induced NASH by reversing metabolic disturbance, relieving oxidative stress and liver injury, and suppressing PKM2-dependent glycolysis and AIM2 inflammasome activation. Macrophage PKM2 acts as a key mediator of pathogenic macrophage-hepatocyte crosstalk, which is critical for the hepatoprotective effects of SGF against NASH. Overall, our study findings highlight SGF as a promising therapeutic option for this specific population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.